Department of Surgery, Division of Surgical Oncology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):555-566. doi: 10.1080/17474124.2021.1890584. Epub 2021 Feb 26.
: Peri-hilar cholangiocarcinoma is an aggressive bile duct cancer. Long-term survival is possible with margin-negative surgery. Historically, unresectable disease was approached with non-curative treatment options. In recent decades, an innovative approach of neoadjuvant chemoradiation and liver transplantation has demonstrated long-term survival for highly selected patients.: This is a critical analysis of studies published to date on neoadjuvant chemoradiation and liver transplantation for selected patients with peri-hilar cholangiocarcinoma. A PubMed literature search was conducted for years 1970-2020 with the following search criteria: ['hilar' OR 'peri-hilar' AND 'cholangiocarcinoma'] AND ['treatment' OR 'transplantation' OR 'survival' OR 'outcome']; 'neoadjuvant chemoradiation' AND 'unresectable cholangiocarcinoma'. All peer-reviewed original research studies were selected for review.: Neoadjuvant chemoradiation and liver transplantation for patients with early stage unresectable peri-hilar cholangiocarcinoma can achieve long-term survival in highly selected patients who survive to transplantation without disease progression. There are observed differences in survival for patients with PSC-associated versus de novo cholangiocarcinoma and transplanted versus resected patients; however, these differences are not contextualized by established tumor and patient factors that influence recurrence and survival. Therefore, these results must be interpreted within the limitations of the study designs upon which they are based.
肝门周围胆管癌是一种侵袭性胆管癌。边缘阴性手术可实现长期生存。历史上,不可切除的疾病采用非治愈性治疗方法。近几十年来,新辅助放化疗和肝移植的创新方法已证明,对于高度选择的患者,可实现长期生存。
本文对迄今为止发表的关于新辅助放化疗和肝移植治疗选择患者肝门周围胆管癌的研究进行了批判性分析。在 1970 年至 2020 年期间,使用以下搜索标准在 PubMed 文献中进行了搜索:['肝门'或'肝门周围'和'胆管癌']和['治疗'或'移植'或'生存'或'结果']; '新辅助放化疗'和'不可切除的胆管癌'。选择所有经过同行评审的原始研究进行综述。
对于早期不可切除的肝门周围胆管癌患者,新辅助放化疗和肝移植可以在没有疾病进展而存活至移植的高度选择患者中实现长期生存。PSC 相关与新发胆管癌以及移植与切除患者的生存存在差异;然而,这些差异并没有通过影响复发和生存的既定肿瘤和患者因素进行背景化。因此,必须在它们所依据的研究设计的局限性内解释这些结果。